

Massive Bio Receives CNIL Certification for GDPR Compliance

Massive Bio is now authorized to process medical records in France, marking a major step in AI-driven clinical trial matching across Europe.

BOCA RATON, FL, UNITED STATES, April 14, 2025 /EINPresswire.com/ -- Massive Bio holds certification from the French Data Protection Authority (CNIL), confirming its compliance with the General Data Protection Regulation (GDPR) and French data privacy laws. This approval allows Massive Bio to securely process patient medical records (MRs) in France via its cloud-based platforms.

This certification comes at a pivotal moment for France's healthcare system, as the country intensifies its investments in artificial intelligence. With €109 billion in AI funding announced in early 2025 and mandatory AI training for healthcare students launching nationwide, France is positioning itself as a European leader in ethical medical innovation^{1 2}.

Massive Bio's AI-powered platform for clinical trial matching aligns with these national efforts to modernize care delivery and improve patient access to cutting-edge research opportunities. The company's compliance with CNIL requirements strengthens its ability to collaborate with healthcare institutions across France.

"Our CNIL certification reaffirms that Massive Bio meets all regulatory standards for processing health data in France," said [Çağatay Çulcuoğlu](#), Co-founder, CTO & COO of Massive Bio. "There are no legal obstacles preventing hospitals and physicians from securely sharing medical records with Massive Bio for clinical trial matching."

"Through CNIL certification, we are expanding our footprint in France by leveraging institutional



agreements,” added Mert Sari, Director, OUS Provider Engagement at Massive Bio. “We are pleased to be the choice of patients and providers in France and remain committed to advancing our growth in the country as well as across Europe.”

Why This Matters

As France accelerates AI integration in areas like precision oncology and health data infrastructure, certified platforms like Massive Bio play a key role in supporting this transition—bridging technology, regulation, and real-world patient impact³.

About Massive Bio

Massive Bio, co-founded by [Selin Kurnaz](#), [Arturo Loaiza-Bonilla](#), and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit www.massivebio.com.

Mert Turkkan

Massive Bio

+1 646-461-4946

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[TikTok](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/803044855>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.